ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
Company facts
| Company | ABVC BioPharma, Inc. |
|---|---|
| Symbol | ABVC |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $26.12M (Massive market data, 2026-09-10) |
| Employees | 19 |
| Country | United States |
| Website | https://www.abvcpharma.com |
Trading — ABVC BioPharma, Inc.
| Last price | $0.98 |
|---|---|
| Change | 0.42% |
| Previous close | $0.98 |
| Day range | $0.98 – $1.01 |
| 50-day average | $1.10 |
| 200-day average | $1.48 |
| Average volume | 96,644 |
Price basis: yfinance_daily_bar_close · 2026-09-11T21:07:44.986755+00:00
Valuation and financial health
| Earnings per share | $-0.13 |
|---|---|
| Price / book | 2.54 |
| Enterprise value / EBITDA | -7.48 |
| Enterprise value / sales | 32.85 |
| Debt / equity | 0.01 |
| Current ratio | 0.07 |
| Dividend yield | 0.00% |
| Free cash flow | -$2.70M |
| Cash ratio | 0.01 |
| Enterprise value | $26.15M |
Reported 2026-09-10
Earnings
| Report date | 2026-10-30 |
|---|---|
| Session | Not Supplied |
| Fiscal quarter ending | Sep/2026 |
| Year-ago EPS | ($0.05) |
| Analyst estimates | 3 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for ABVC are on the IntelTrends dashboard.